FTD-GRN
Clinical trials for FTD-GRN explained in plain language.
Never miss a new study
Get alerted when new FTD-GRN trials appear
Sign up with your email to follow new studies for FTD-GRN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Brain-Delivered gene therapy tested to halt devastating Early-Onset dementia
Disease control Recruiting nowThis early-phase study is testing a one-time gene therapy called AVB-101 for people with a specific genetic form of frontotemporal dementia (FTD-GRN). The therapy is designed to be delivered directly into the brain to restore a missing protein and potentially slow or stop disease…
Matched conditions: FTD-GRN
Phase: PHASE1, PHASE2 • Sponsor: AviadoBio Ltd • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Brain injection aims to halt devastating dementia
Disease control Recruiting nowThis early-stage study is testing a one-time gene therapy called PBFT02 for adults with specific genetic forms of frontotemporal dementia (FTD). The therapy is delivered via a single injection into the spinal fluid, aiming to deliver a working copy of a missing or faulty gene to …
Matched conditions: FTD-GRN
Phase: PHASE1, PHASE2 • Sponsor: Passage Bio, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC